30 July 2021 - The U.S. FDA today revised the emergency use authorisation for REGEN-COV (casirivimab and imdevimab, administered together) authorising REGEN-COV for emergency use as post-exposure prophylaxis for COVID-19 in adults and paediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalisation or death. 

REGEN-COV is not authorised for pre-exposure prophylaxis to prevent COVID-19 before being exposed to the SARS-CoV-2 virus -- only after exposure to the virus.

Read FDA press release